Shire looks to new launches to offset Adderall loss
30 October 2009
Simon Varcoe
Please Login to read the full article.
30 October 2009
Simon Varcoe
simon.varcoe@informa.com
Shire Pharmaceuticals continued to suffer from generic competition in the third quarter as its total sales slumped by 15% to $603 million.
The decline in sales of its attention-deficit hyperactivity disorder (ADHD) treatment Adderall XR, due to generic competition from Teva, continued apace,...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
